http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101147308-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 |
| filingDate | 2005-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101147308-B1 |
| titleOfInvention | Hypertension Drugs |
| abstract | Nicardipine or its salts are intended to remove application limitations in cases of increased intracranial pressure in the acute phase of stroke that has been contraindicated. In the rat cerebral infarction model, even when the intracranial pressure is advancing in the acute stage of onset, it was found that nicardipine or its salt does not affect intracranial pressure unlike conventional recognition, thus completing the present invention. That is, the present invention provides a therapeutic agent for hypertension of a patient in whom intracranial pressure is advancing in the acute phase of stroke, which contains nicardipine or a salt thereof as an active ingredient. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105921223-A |
| priorityDate | 2004-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.